PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

(2016) Amirhossein Sahebkar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Inflammatory cytokines in atherosclerosis: current therapeutic approaches

(2016) Dimitris Tousoulis et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials

(2015) Gabriella Passacquale et al.   CARDIOVASCULAR RESEARCH

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia

(2014) Diederik F. van Wijk et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

In Vivo Imaging of Enhanced Leukocyte Accumulation in Atherosclerotic Lesions in Humans

(2014) Fleur M. van der Valk et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation

(2013) Ahmed Tawakol et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Monocytes in Coronary Artery Disease and Atherosclerosis

(2013) Angie Ghattas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Relationship of Serum Inflammatory Biomarkers With Plaque Inflammation Assessed by FDG PET/CT

(2013) Raphaël Duivenvoorden et al.   JACC-Cardiovascular Imaging

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14hi/CD16neg monocytes: Expansion of CD14hi/CD16pos and contraction of CD14lo/CD16pos monocytes in acute liver fail

(2012) Robin Daniel Abeles et al.   CYTOMETRY PART A

PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages

(2012) ZHIHAN TANG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

(2011) Nicola Ferri et al.   ATHEROSCLEROSIS

Monocytes of patients with familial hypercholesterolemia show alterations in cholesterol metabolism

(2008) Sandy Mosig et al.   BMC Medical Genomics

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE−/− mice

(2007) Glenys A. Tennent et al.   ATHEROSCLEROSIS